Novel Potential Markers of Metabolic Dysfunction–Associated Steatohepatitis Prone to Hepatocellular Carcinoma
Canadian Journal of Gastroenterology and Hepatology · 2026-01 · 2026 (1)
DOI: 10.1155/cjgh/7390933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 26.05.2026. Verfasst von Chen Ling und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629,…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes for Food and Drug Control.
Abstract (Originalsprache)
Background
Metabolic dysfunction–associated steatohepatitis (MASH), the progressive phenotype of metabolic dysfunction–associated steatotic liver disease (MASLD), is well recognized for its increased risk of progressing to cirrhosis and hepatocellular carcinoma (HCC). However, early diagnosis and identification of the MASH patients with a tendency toward malignancy HCC remain a significant challenge.
Method
In previous studies, we established a novel conditional inducible HRAS gene expression murine model with normal diet and lifestyle conditions, which exhibited 100% HCC incidence and recapitulated the four major progression stages of MASH to HCC: MASH, fibrosis, cirrhosis, and HCC. Based on this model, we revealed the potential markers of MASH prone to HCC characteristics of malignant MASH through RNA‐Seq and bioinformatics analysis, and further confirmed by pathological biopsy, biochemical tests, inflammatory cytokines measurement, Oil O red staining, and immunohistochemical examination.
Results
For MASH, the initial stage of HCC, we observed evidence of hyperlipidemia and insulin resistance in the HRAS mouse model based on blood morphology, biochemical parameters, and insulin tolerance test. Furthermore, the pathological features of MASH were confirmed by the presence of hepatocellular fatty vacuolar changes, lipid droplet accumulation, and inflammation. Then, RNA‐Seq analysis revealed the molecular signatures of malignant MASH and revealed three novel potential markers associated with adverse progression of MASH to HCC: Klk1b4, Alox5 , and Pla2g2e .
Conclusion
Based on a stable and novel murine model of MASH prone to HCC, we, for the first time, presented a comprehensive molecular signature and identified novel potential adverse progression markers of MASH prone to malignant HCC, which contributed possibly to early clinical diagnosis and prognostic assessment, even becoming potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
- National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control (NIFDC), Beijing, 100176, China.
- Division of HIV, AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Products Control, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
- Division of Laboratory Animal Monitoring, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing, 102629, China.
- Novogene Co., Ltd., Beijing, 10015, China.
- College of Life Science School, Provincial Key Laboratory of Biotechnology of Shaanxi Province, Northwest University, Xi'an, Shaanxi, 710069, China, nwu.edu.cn.
ORCID-Profile: Chen Ling, Yuya Wang, Susu Liu, Haoyang Zhao, Yuwei Zhao, Changfa Fan
Förderung
- National Institutes for Food and Drug Control
Zitieren
APA
Ling, C., Wang, Y., Liu, S., Huo, G., Yang, Y., Xu, N., Wang, H., Zhao, H., Zhang, Z., Fu, R., Zhao, Y., & Fan, C. (2026). Novel Potential Markers of Metabolic Dysfunction–Associated Steatohepatitis Prone to Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology, 2026(1). https://doi.org/10.1155/cjgh/7390933
Vancouver
Ling C, Wang Y, Liu S, Huo G, Yang Y, Xu N, et al. Novel Potential Markers of Metabolic Dysfunction–Associated Steatohepatitis Prone to Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology. 2026;2026(1). doi:10.1155/cjgh/7390933
BibTeX
@article{Ling2026,
author = {Ling, Chen and Wang, Yuya and Liu, Susu and Huo, Guitao and Yang, Yanwei and Xu, Nan and Wang, Hong and Zhao, Haoyang and Zhang, Zeqiang and Fu, Rui and Zhao, Yuwei and Fan, Changfa},
title = {Novel Potential Markers of Metabolic Dysfunction–Associated Steatohepatitis Prone to Hepatocellular Carcinoma},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cjgh/7390933}
}
EUVIMED